Jan Willem van der Laan
Van der Laan, Jan Willem
Laan, Jan Willem van der
VIAF ID: 305025494 (Personal)
Permalink: http://viaf.org/viaf/305025494
Preferred Forms
- 100 0 _ ‡a Jan Willem van der Laan
-
- 100 1 _ ‡a Laan, Jan Willem van der
- 100 1 _ ‡a Van der Laan, Jan Willem
- 100 1 _ ‡a Van der Laan, Jan Willem
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells | |
Animal-free applications in the development of cell-based therapies | |
Animal models in influenza vaccine testing. | |
Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: a workshop summary | |
Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union | |
Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects | |
Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties | |
A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies | |
Current status and burning issues in immunotoxicity testing of drugs | |
Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices | |
Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective | |
Global approach in safety testing : ICH guidelines explained | |
Human and environmental health challenges for the next decade (2010–2020). | |
Immune function testing of human pharmaceuticals: regulatory overshoot? | |
Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production | |
An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies | |
Knowledge sharing to facilitate regulatory decision-making in regard to alternatives to animal testing: Report of an EPAA workshop | |
Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse model | |
New adjuvanted vaccines in pregnancy: what is known about their safety? | |
Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls | |
Oseltamivir and breastfeeding | |
Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents | |
Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products | |
The RETHINK project--minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment | |
Testing strategies for embryo-fetal toxicity of human pharmaceuticals. Animal models vs. in vitro approaches: a workshop report | |
Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals | |
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence | |
The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI |